

## Cariprazine Publications 2006-2021

### Non-clinical

#### Chemistry

[Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents](#)


Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B  
*J Pharmaceut Biomed Anal* **48**: 678-684; 2008

[Discovery of cariprazine \(RGH-188\): A novel antipsychotic acting on dopamine D3/D2 receptors](#)

Ágai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt É, Kiss B, Vastag M, Tihanyi K, Sággy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, M. Kapás, Z. Szombathelyi  
*Bioorg Med Chem Lett* **22**: 3437-3440; 2012

[Discovery of cariprazine \(chemical aspects\)](#) (published in Hungarian)  Open access

Domány Gy  
*Magyar Kémikusok Lapja* **71**: 261-262; 2016

[The chemistry that lead to cariprazine](#) (published in Hungarian with English abstract)  Open access

Domány Gy, Greiner I  
*Magyar Kémiai Folyóirat* **122**: 112-116; 2016

#### Neurochemistry

[Cariprazine \(RGH-188\), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile](#)

Kiss B, Horváth A, Némethy Z, Schmidt É, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Ágai-Csongor É, Domány G, Tihanyi K, Adham N, Szombathelyi Z  
*J Pharmacol Exp Ther* **333**: 328-340; 2010

[Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine \(RGH-188\), in monkey brain measured using positron emission tomography](#)

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B  
*Psychopharmacology* **218**: 579-587; 2011

[In vitro and in vivo comparison of \[3H\]\(+\)-PHNO and \[3H\]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites](#)


Kiss B, Horti F, Bobok A  
*Synapse* **65**: 467-478; 2011

[Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist \[11C\]-cariprazine: An in vivo positron emission tomography study in non-human primates](#)


Tóth M, Varróné A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B  
*Synapse* **67**: 258-264; 2013

[Long-term effects of cariprazine exposure on dopamine receptor subtypes](#)


Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI  
*CNS Spectrums* **19**: 268-277; 2014

[Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine](#)  Open access

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI  
*CNS Spectrums*, **22**: 484-494; 2017

[Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity](#)  Open access

Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N  
*Psychopharmacology* **235**: 1593–1607; 2018

[Involvement of 5-HT1A and 5-HT2A receptors but not  \$\alpha\$ 2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo](#)  Open access

Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P  
*Mol Pharmacol* **94**: 1363-1370; 2018

[The role of dopamine D<sub>3</sub> receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens](#)

Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY  
*J Pharm Exp Ther* **371**: 517-525; 2019

[Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin<sub>1A</sub> receptor neurotransmission in the hippocampus](#)

El Mansari M, Ebrahimzadeh M, Hamati R, Iro CM, Farkas B, Kiss B, Adham N, Blier P  
*J Psychopharmacol* 1-12; 2020; doi: 10.1177/0269881120936891

### Pharmacology

[RGH-188, a potent D<sub>3</sub>/D<sub>2</sub> dopamine receptor partial agonist, binds to dopamine D<sub>3</sub> receptors in vivo and shows antipsychotic-like and pro-cognitive effects in rodents](#)

Gyertyán I, Kiss B, Sággy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájér-Balázs M, Kapás M, Ágai-Csongor É, Domány G, Tihanyi K, Szombathelyi Z  
*Neurochemistry International* **59**: 925-935; 2011

[Cariprazine, a dopamine D<sub>3</sub>-receptor-preferring partial agonist, block phencyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.](#)

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C  
*Psychopharmacology* **226**: 91-100; 2013

[Cariprazine \(RGH-188\), a D<sub>3</sub>-preferring dopamine D<sub>3</sub>/D<sub>2</sub> receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats](#)

Román V, Gyertyán I, Sággy K, Kiss B, Szombathelyi Z  
*Psychopharmacology* **226**: 285-293; 2013

[Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression](#)


Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I  
*Behav Pharmacol* **25**: 567-574; 2014

[Cariprazine exerts antimanic properties and interferes with dopamine D<sub>2</sub> receptor  \$\beta\$ -arrestin interactions](#)  Open access

Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS  
*Pharma Res Per* **3**: e00073, 1-10; 2014

[Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices](#)


El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N  
*Psychiatry Res* **229**: 370-373; 2015

[Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology](#)  Open access

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N  
*Eur Neuropsychopharmacol* **26**: 3-14; 2016

[The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia](#)


Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC  
*Eur Neuropsychopharmacol* **26**: 208-224; 2016

[Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model](#)  Open access


Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS  
*Int J Neuropsychopharmacol* **20**: 788-796; 2017

[The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task](#)  Open access


Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B  
*Psychopharmacology* **235**: 1403-1414; 2018

[The novel atypical antipsychotic cariprazine demonstrates dopamine D<sub>2</sub> receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity](#)  Open access

Delcourte S, Ashby CR, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N  
*CNS Neurosci. Ther.* **24**: 1129-1139; 2018

[Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine](#)  Open access

Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sággy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B  
*Drug Des Develop Ther* **13**: 3229-3248; 2019

[The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices](#)  Open access

Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z  
*Br J Pharmacol* 1-13; 2020; doi: 10.1111/bph.14923

[Cariprazine modulates sleep architecture in rats](#)

Nyitrai G, Kiss B, Farkas B, Balázs O, Diószegi P, Lendvai B, Czurkó A  
*J Psychopharmacol* **35**: 303-310; 2021

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of Autism Spectrum Disorder

Román V, Adham N, Foley A, Hanratty L, Farkas B, Lendvai B, Kiss B  
*Psychopharmacol* **in press**; 2021


*Pharmacokinetic*

[Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine](#)

Pásztor Mészáros G, Ágai-Csongor É, Kapás M  
*J Pharmaceut Biomed Anal* **48**: 388-397; 2008

## Clinical


### Schizophrenia

[An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial](#)  Open access

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I  
*Schizophr Res* **152**: 450-457; 2014

[Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial](#)  Open access

Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY  
*J Clin Psychiatry* **76**: e1574-e1582; 2015

[Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial](#)  Open access

Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S  
*J Clin Psychopharmacol* **35**: 367-373; 2015

[Cariprazine in the treatment of schizophrenia: A proof-of-concept trial](#)  Open access


Durgam S, Litman R, Papadakis K, Li D, Németh G, Laszlovszky I  
*Int Clin Psychopharmacol* **31**: 61-68; 2016

[Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial](#)  Open access

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA  
*Schizophr Res* **176**: 264-271; 2016

[The effect of cariprazine on hostility associated with schizophrenia](#)  Open access


Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I  
*J Clin Psychiatry* **77**: 109-115; 2016

[Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial](#)  Open access at Richter website


Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW  
*Lancet* **389**: 1103-1113; 2017

[Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study](#)  Open access


Cutler A, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G  
*CNS Spectrums* **23**: 39-50; 2018

[Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study](#)  Open access

Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S  
*Psychopharmacology* **234**: 199-209; 2017

[Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies](#)  Open access


Earley W, Durgam S, Lu K, Laszlovszky I, DeBelle M, Kane JM  
*Int Clin Psychopharmacol* **32**: 319-328; 2017

[The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis](#)  Open access


Nasrallah H, Earley W, Cutler A, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S  
*BMC Psychiatry* **17**: 305; 2017

[Negative symptoms of schizophrenia: Constructs, burden, and management](#)  Open access


Barabácssy A, Szatmári B, Laszlovszky I, Németh G  
Psychotic Disorders: An Update; Edited by Federico Durbano, IntechOpen, pp. 43-62; 2018  
ISBN 978-953-51-5976-6; <http://dx.doi.org/10.5772/intechopen.73300>

[Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data](#)  Open access


Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, Patel M, Barabácssy A, Szatmári B, Németh G  
*Schizophr Res* **204**: 282-288; 2019

[Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial](#)  Open access


Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W  
*J Clin Psychiatry* **80**: 18m12495; 2019

[Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies](#)  Open access


Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S  
*Eur Neuropsychopharmacol* **29**: 127-136; 2019

[The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors](#)  Open access

Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabácssy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G  
*Eur Psychiatry* **58**: 1-9; 2019

[Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia](#)  Open access

Leucht S, Barabácssy A, Laszlovszky I, Szatmári B, Acsai K, Szalai E, Harsányi J, Earley W, Németh G  
*Neuropsychopharmacol* **44**: 1589-1596; 2019

[Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation](#)  Open access


Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabácssy Á, Patel M, Earley W  
*Neuropsychiatr Dis Treat* **15**: 2537–2550; 2019

[Cariprazine safety in adolescents and the elderly: Analyses of clinical study data](#)  Open access


Szatmári B, Barabássy Á, Harsányi J, Laszlovszky I, Sebe B, Gál M, Shiragami K, Németh G  
*Front Psychiatry* **11**: article 61 (1-11); 2020

[Cariprazine therapy in the spirit of functionality – new ways in schizophrenia treatment \(Published in Hungarian with English abstract\)](#)

Laszlovszky I, Barabássy Á, Németh G  
*Psychiat Hung* **35** (Suppl 1): 12–26; 2020

[Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies](#)  Open access

Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G  
*Neuropsych Dis Treat* **17**: 957-970; 2021


[Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety](#)  Open access

Laszlovszky I, Barabássy Á, Németh G  
*Adv Ther* <https://doi.org/10.1007/s12325-021-01797-5>; 2021

### Mania

[The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial](#)  Open access

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I  
*Bipolar Disord* **17**: 63-75; 2015

[Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial](#)  Open access


Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S  
*J Affect Disord* **174**: 296-302; 2015

[Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder](#)  Open access


Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S  
*J Clin Psychiatry* **76**: 284-292; 2015

[Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials](#)  Open access


Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S  
*Eur Neuropsychopharm* **25**: 1882-1891; 2015

[Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies](#)  Open access


Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN  
*J Affect Disord* **215**: 205-212; 2017

[The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study](#)  Open access

Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G  
*J Affect Disord* **225**: 350-356; 2018


[Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder](#)  Open access

Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, Yatham LN  
*J Affect Disord* **226**: 239-244; 2018

[Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials](#)  Open access

McIntyre RS, Masand PS, Earley W, Patel M  
*J Affect Disord* **257**: 600-606; 2019

### Schizophrenia & Mania

[Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis](#)  Open access

Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE  
*Int J Clin Pract* e13037; 2017


### Bipolar Depression

[An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression](#)  Open access


Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, Vieta E, Calabrese JR, Yatham LN  
*Am J Psychiatry* **173**: 271-281; 2016

[Cariprazine treatment of bipolar depression: A randomized, double blind, placebo-controlled phase 3 study](#)  Open access


Earley W, Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN  
*Am J Psychiatry* **176**: 439–448; 2019

[Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies](#)  Open access


McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM  
*CNS Spectrums* **25**: 502–510; 2020

[A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression](#)  Open access


Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN  
*J Affect Disord* **263**: 386-395; 2020

[Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial](#)  Open access

Yatham LN, Vieta E, Earley WR  
*Int Clin Psychopharmacol* **35**: 147–156; 2020

[Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study](#)  Open access

Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR  
*Bipolar Disord* **22**:372–384; 2020

[Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications](#)  Open access

Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W  
*Prim Care Companion CNS Disord* **22**: 20m02611; 2020

[Efficacy of cariprazine in bipolar I depression across patient characteristics: A post hoc analysis of pooled randomized, placebo-controlled studies](#)  Open access

Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN  
*Int Clin Psychopharmacol* **36**: 76-83; 2021


[Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression](#)  Open access

Citrome L, Yatham LN, Patel MD, Barabácssy Á, Hankinson A, Earley WR  
*J Affect Disord* **288**: 191-198; 2021


[The efficacy of cariprazine on function in patients with bipolar depression: A post hoc analysis of a randomized controlled trial](#)

Vieta E, Calabrese JR, Whelan J, Tohen M, Earley WR  
*Curr Med Res Opin* <https://doi.org/10.1080/03007995.2021.1932446>; 2021

### Major Depression add-on

[Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients](#)  Open access

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA  
*J Clin Psychiatry* **77**: 371-378; 2016

[Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial](#)  Open access

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G  
*Int Clin Psychopharmacol* **33**: 312-321; 2018

[Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial](#)

Earley W, Guo H, Németh G, Harsányi J, Thase M  
*Psychopharmacology Bulletin* **48**: 62-80; 2018

[Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder](#)

 Open access


Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabácssy Á, Németh G  
*Int Clin Psychopharmacol* **34**: 76-83; 2019

### Other Indications

[Wernicke–Korsakoff syndrome associated with mtDNA disease](#)  Open access


Jimoh IJ, Sebe B, Balicza P, Fedor M, Pataky I, Rudas G, Gál A, Inczédy-Farkas G, Németh G, Molnár MJ  
*Ther Adv Neurol Disord* **13**: 1–7; 2020

### Human Pharmacokinetic

[Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand \[11C\]-\(+\)-PHNO](#)  Open access

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A  
*Psychopharmacology* **233**: 3503-3512; 2016




[Clinical pharmacology study of cariprazine \(MP-214\) in patients with schizophrenia \(12-week treatment\)](#)  Open access

Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y  
*Drug Design Develop Ther* **10**: 327-338; 2016

[Comment on: “Clinical pharmacokinetics of atypical antipsychotics: An update”](#)  Open access

Periclou A, Riccobene T, Kapás M, Laszlovszky I  
*Clinical Pharmacokinet* **58**: 1215-1216; 2019


[Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania](#)  Open access

Periclou A, Willavize S, Jaworowicz D, Passarell J, Carrothers T, Ghahramani P, Durgam S, Earley W, Kapás M, Khariton T  
*Clin Transl Sci* **13**: 362–371; 2020

[Population pharmacokinetics of cariprazine and its major metabolites](#)  Open access


Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T  
*Eur J Drug Metab PK*, in press; 2020; doi 10.1007/s13318-020-00650-4

### Post-marketing trials

[The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: An observational study](#)  Open access

Rancans E, Dombi ZB, Mátrai P, Barabácssy Á, Sebe B, Skrivele I, Németh G  
*Int Clin Psychopharmacol* **36**: 154–161; 2021


### **Health Technology Assessment (HTA)**

[Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone](#)  Open access


Németh B, Molnár A, Akehurst R, Horváth M, Kóczyán K, Németh G, Götze Á, Vokó Z  
*J Comp Eff Res* **6**: 639-648; 2017

[Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia](#)

Németh B, Bendes R, Nagy B, Götze Á, Kóczyán K, Horváth M, Deák I, Tóth B, Kaló Z  
*Health Policy Tech* **8**: 84-91; 2019

[Population-level QALY gain estimates with the use of cariprazine for patients with negative symptoms of schizophrenia in Hungary \(Published in Hungarian with English abstract\)](#)  Open access

Bendes R, Németh B, Pitter JG, Kóczyán K, Götze Á, Kaló Z  
*LAM* **29**:467–475; 2019

[Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine](#)  Open access

Vokó Z, Bitter I, Mersich B, Réthelyi J, Molnár A, Pitter JG, Götze Á, Horváth M, Kóczyán K, Fonticoli L, Lelli F, Németh B  
*Cost Eff Resour Alloc* **18**:28; 2020

## General


[Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.](#)

[A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications \(Published in Hungarian with English abstract\)](#)

Laszlovszky I, Németh G  
*Gyógyszerészet* **59**: 643-646; 2015

In nutshell about cariprazine (Published in Hungarian)

Laszlovszky I, Barabássy Á  
*Psychiatric and Neurology Times* – Hungarian edition, (5) 26-28, 2018

[Cariprazine, a new type – dopamine D<sub>3</sub> receptor preferring – partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms. \(Published in Hungarian with English abstract\)](#)  Open access

Laszlovszky I, Kiss B, Barabássy Á, Kapás M, Németh G  
*Neuropsychopharmacol Hung* **21**: 103-118; 2019

Cariprazine (Reagila®) – a new mechanism of action antipsychotic with unique therapeutic possibilities for the treatment of schizophrenia and other psychiatric dysfunctions (Published in Hungarian with English abstract)

Laszlovszky I, Kiss B, Domány G, Kapás M, Barabássy Á, Szatmári B, Szombathelyi Z, Németh G, Greiner I  
*Gyógyszerészet* **64**: 707-713, 2020